Discover how rheumatoid arthritis advances through distinct stages, the symptoms at each phase, and treatment approaches that ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing -HAMPTON, N.J., ...

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP ...

Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.